CD34 and acute myeloid leukemia: The two clusters did not differ with regard to AML etiology (de novo versus secondary/relapse) differentiation (FAB classification or CD34 stem cell marker expression), cytogenetic abnormalities, and/or frequency of NPM1 or FLT3 mutations (Table 3).